---
title: Distinguish Parkinson from similar conditions
nct_id: NCT06501469
status: RECRUITING
sponsor: "Non-profit organization for scientific research in Parkinson's disease and related disorders"
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06501469"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06501469"
last_fetched: "2026-05-10T14:06:48.116Z"
source: "Parkinson's Pathways (curated)"
---
# Distinguish Parkinson from similar conditions

**Goal (in five words):** Distinguish Parkinson from similar conditions

**Official Title:** Prospective, Observational Study to Identify Biomarkers in Parkinsonian Syndromes

**Trial ID:** [NCT06501469](https://clinicaltrials.gov/study/NCT06501469)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Non-profit organization for scientific research in Parkinson's disease and related disorders
- **Target Enrollment:** 200 participants
- **Start Date:** 2022-03-23
- **Completion Date:** 2029-03-25
- **Conditions:** Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Atypical Parkinsonism, Parkinsonism

## Summary For Families

The goal is to identify biological markers that can tell Parkinson's disease apart from related parkinsonian syndromes and track disease progression, so diagnosis and future treatments can be improved. The team will observe participants over time and collect clinical data, imaging, blood or CSF samples, and digital/monitoring data to find molecules or patterns linked to specific diagnoses and symptoms, no experimental drug is given, and current treatments like levodopa are recorded to see how biomarkers relate to medication response. People who can give written consent are eligible, including those with parkinsonism of any duration and healthy controls; excluded are drug- or metabolic-induced parkinsonism, structural brain lesions that explain symptoms, other serious illnesses with life expectancy under five years, or active participation in other interventional trials.

## Eligibility

- **Sex:** ALL

### Full Criteria

```
IΙnclusion Criteria:

* Written informed consent, including consent to monitoring
* Patients with Parkinsonism and disease duration \< 2 years
* Patients with Parkinsonism and disease duration \> 2 years
* Healthy individuals without any neurological disease

Exclusion Criteria:

* Drug-induced parkinsonism (eg, neuroleptics, lithium, valproic acid, metoclopramide).
* Metabolic conditions related parkinsonism (eg, Wilson's disease, hypoparathyroidism).
* Structural lesions on brain magnetic resonance imaging (MRI) that explain the symptoms, such as normal pressure hydrocephalus, moderate to severe chronic vascular encephalopathy, cerebral infarction, neoplasm
* Other serious diseases that indicate a life expectancy of \<5 years.
* Active participation in other interventional clinical studies
```

## Locations (1)

- HYGEIA Hospital, Parkinson's disease and Movement Disorders Department, Athens, Greece _(37.9838, 23.7278)_
  - Maria Stamelou, Prof Dr — (CONTACT) — +302106867000 — mstamelou@hygeia.gr

## Central Contacts

- Maria Stamelou, Prof Dr — (CONTACT) — +302106867303 — mstamelou@hygeia.gr

---

*Canonical: https://parkinsonspathways.com/trial/NCT06501469*  
*HTML version: https://parkinsonspathways.com/trial/NCT06501469*  
*Source data: https://clinicaltrials.gov/study/NCT06501469*